DR. ALAIN THIBAULT, M.D.
Osteopathic Medicine at Singleton Dr, Bethesda, MD
License number
Maryland 0101052822
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
9607 Singleton Dr, Bethesda, MD 20817
Phone
(301) 564-5757
Personal information
See more information about ALAIN THIBAULT at radaris.comName
Address
Phone
10401 Grosvenor Pl, Rockville, MD 20852
9607 Singleton Dr, Bethesda, MD 20817
5805 Beech Ave, Bethesda, MD 20817
Professional information
Method Of Treating Cancer With Dll4 Antagonist And Chemotherapeutic Agent
US Patent:
2013030, Nov 14, 2013
Filed:
Jul 23, 2013
Appl. No.:
13/948919
Inventors:
Gavin Thurston - White Plains NY, US
Alain Thibault - Bethesda MD, US
Alain Thibault - Bethesda MD, US
International Classification:
A61K 39/395, A61K 45/06
US Classification:
4241741
Abstract:
The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.
Method Of Treating Cancer With Dll4 Antagonist And Chemotherapeutic Agent
US Patent:
2010033, Dec 30, 2010
Filed:
Jun 25, 2010
Appl. No.:
12/823680
Inventors:
GAVIN THURSTON - WHITE PLAINS NY, US
ALAIN THIBAULT - BETHESDA MD, US
ALAIN THIBAULT - BETHESDA MD, US
Assignee:
REGENERON PHARMACEUTICALS, INC. - TARRYTOWN NY
International Classification:
A61K 39/395, A61P 35/00, B65D 71/00
US Classification:
4241741, 206223
Abstract:
The invention provides methods for treating various types of cancer/tumor by administering the combination of DII4 antagonists, in particular, DII4 antibodies and fragments thereof that specifically bind human DII4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing DII4 antagonists and chemotherapeutic agents are also provided.
Dr. Alain Thibault, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
9607 Singleton Dr, Bethesda 20817
(301) 564-5757 (Phone)
(301) 564-5757 (Phone)
Languages:
English